Retatrutide 10mg

Overview

Retatrutide (LY3437943) is a next-generation synthetic peptide described as a triple agonist of the GIP, GLP-1 and glucagon receptors. It ranks among the most studied molecules in energy-metabolism research. Supplied in a lyophilised vial for experimental, in vitro and preclinical use only.

Mechanism of action

Retatrutide is distinguished by simultaneous action on three signalling pathways:

• GLP-1 receptor — studied for its role in blood-glucose regulation and satiety.
• GIP receptor — involved in the insulin response and lipid metabolism.
• Glucagon receptor — associated with energy expenditure and mobilisation of reserves.

This triple activation makes it a singular research model for studying integrated metabolic mechanisms.

Research context

Retatrutide is the subject of a large clinical programme. In the phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023; 338 participants), reported data indicated a mean body-weight reduction of up to ~24 % at 48 weeks at the highest dose. The molecule is also being evaluated in type 2 diabetes and hepatic steatosis (MASLD). These data pertain to clinical research conducted on the molecule and in no way constitute an indication or usage advice.

Quality assurance

• Purity ≥ 99 % verified by HPLC
• Certificate of Analysis (COA) available per batch
• Traceability: unique batch number on every vial

Format & handling

Presentation: lyophilised powder, 10 mg / vial · Reconstitution: bacteriostatic water · Storage: refrigerate the lyophilisate; after reconstitution, keep cold and protected from light.

Research FAQ

How does it differ from semaglutide or tirzepatide?
Semaglutide targets the GLP-1 receptor alone; tirzepatide acts on GLP-1 and GIP; retatrutide adds glucagon-receptor activation (triple agonist).

What is its regulatory status?
An experimental molecule in clinical development (phase 3), approved by neither the FDA nor the EMA. For research use only.

References

• Jastreboff AM et al. « Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. » N Engl J Med, 2023. DOI: 10.1056/NEJMoa2301972
• Retatrutide in hepatic steatosis (MASLD) — randomised phase 2a trial, Nature Medicine, 2024.